Literature DB >> 12503828

Comparison of the effects of antidepressants on norepinephrine and serotonin concentrations in the rat frontal cortex: an in-vivo microdialysis study.

Chad E Beyer1, Steve Boikess, Bin Luo, Lee A Dawson.   

Abstract

The present study employed in-vivo microdialysis techniques in the freely moving rat to systematically compare the neurochemical effects of various antidepressant agents on extracellular concentrations of norepinephrine (NE) and serotonin (5-HT) in the frontal cortex. We found that acute administration of the tricyclic antidepressant, desipramine (3-30 mg/kg, s.c.) and the dual serotonin/norepinephrine reuptake inhibitor, venlafaxine (3-30 mg/kg, s.c.), produced dose-dependent and robust increases in cortical NE concentrations (498% and 403%, respectively). Conversely, acute injection of the selective serotonin reuptake inhibitors, fluoxetine (30 mg/kg, s.c.) and paroxetine (1-10 mg/kg, s.c.), did not alter forebrain NE concentrations. However, paroxetine did produce a significant increase in cortical NE concentrations (164%) when administered at 30 mg/kg. These changes in NE were not paralleled by 5-HT, which showed no increase following administration of desipramine, venlafaxine, paroxetine or fluoxetine. Combination treatment with the 5-HT1A receptor antagonist, WAY-100635 (0.3 mg/kg, s.c.), significantly enhanced extracellular 5-HT concentrations following venlafaxine (10 and 30 mg/kg), fluoxetine (30 mg/kg) and paroxetine (3-30 mg/kg). Alternatively, WAY-100635 produced no augmentation of the antidepressant-induced changes in extracellular NE. Collectively, these studies show that paroxetine, at low to intermediate doses, and fluoxetine are selective for 5-HT versus NE systems, whereas venlafaxine produces similar effects on both 5-HT and NE levels at the effective doses tested.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12503828     DOI: 10.1177/026988110201600403

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN: 0269-8811            Impact factor:   4.153


  24 in total

1.  Preclinical characterization of WAY-211612: a dual 5-HT uptake inhibitor and 5-HT (1A) receptor antagonist and potential novel antidepressant.

Authors:  C E Beyer; Q Lin; B Platt; J Malberg; G Hornby; K M Sullivan; D L Smith; T Lock; P J Mitchell; N T Hatzenbuhler; D A Evrard; B L Harrison; R Magolda; M N Pangalos; L E Schechter; S Rosenzweig-Lipson; T H Andree
Journal:  Br J Pharmacol       Date:  2009-03-26       Impact factor: 8.739

2.  Effects of amantadine and budipine on antidepressant drug-evoked changes in extracellular 5-HT in the frontal cortex of freely moving rats.

Authors:  Jenny C E Owen; Peter S Whitton
Journal:  Br J Pharmacol       Date:  2005-07       Impact factor: 8.739

3.  Subanesthetic doses of ketamine transiently decrease serotonin transporter activity: a PET study in conscious monkeys.

Authors:  Shigeyuki Yamamoto; Hiroyuki Ohba; Shingo Nishiyama; Norihiro Harada; Takeharu Kakiuchi; Hideo Tsukada; Edward F Domino
Journal:  Neuropsychopharmacology       Date:  2013-07-24       Impact factor: 7.853

4.  Implication of 5-HT2 receptor subtypes in the mechanism of action of antidepressants in the four plates test.

Authors:  Bríd Aine Nic Dhonnchadha; Nadège Ripoll; Florence Clénet; Martine Hascoët; Michel Bourin
Journal:  Psychopharmacology (Berl)       Date:  2004-11-18       Impact factor: 4.530

5.  Changes in intensity of serotonin syndrome caused by adverse interaction between monoamine oxidase inhibitors and serotonin reuptake blockers.

Authors:  Rui Tao; Mary Rudacille; Gongliang Zhang; Zhiyuan Ma
Journal:  Neuropsychopharmacology       Date:  2014-02-28       Impact factor: 7.853

6.  Association of changes in norepinephrine and serotonin transporter expression with the long-term behavioral effects of antidepressant drugs.

Authors:  Zaorui Zhao; Han-Ting Zhang; Elianna Bootzin; Mark J Millan; James M O'Donnell
Journal:  Neuropsychopharmacology       Date:  2008-10-15       Impact factor: 7.853

7.  Norepinephrine-deficient mice lack responses to antidepressant drugs, including selective serotonin reuptake inhibitors.

Authors:  John F Cryan; Olivia F O'Leary; Sung-Ha Jin; Julie C Friedland; Ming Ouyang; Bradford R Hirsch; Michelle E Page; Ashutosh Dalvi; Steven A Thomas; Irwin Lucki
Journal:  Proc Natl Acad Sci U S A       Date:  2004-05-17       Impact factor: 11.205

8.  Paroxetine combined with a 5-HT(1A) receptor antagonist reversed reward deficits observed during amphetamine withdrawal in rats.

Authors:  Athina Markou; Amanda A Harrison; Jessica Chevrette; Daniel Hoyer
Journal:  Psychopharmacology (Berl)       Date:  2004-09-25       Impact factor: 4.530

9.  The antidepressive effects of exercise: a meta-analysis of randomized trials.

Authors:  Chad D Rethorst; Bradley M Wipfli; Daniel M Landers
Journal:  Sports Med       Date:  2009       Impact factor: 11.136

Review 10.  Innovative approaches for the development of antidepressant drugs: current and future strategies.

Authors:  Lee E Schechter; Robert H Ring; Chad E Beyer; Zoë A Hughes; Xavier Khawaja; Jessica E Malberg; Sharon Rosenzweig-Lipson
Journal:  NeuroRx       Date:  2005-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.